Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics-Reference-Cited by-同舟云学术

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics

Published:2021-05-25 Issue:1 Volume:194 Page:120-131
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Harrison Simon J.¹^ORCID,Perrot Aurore²^ORCID,Alegre Adrian³,Simpson David⁴,Wang Ming Chung⁵,Spencer Andrew⁶,Delimpasi Sosana⁷,Hulin Cyrille⁸,Sunami Kazutaka⁹,Facon Thierry¹⁰,Vlummens Philip¹¹,Yong Kwee¹²^ORCID,Campana Frank¹³¹⁴,Inchauspé Marlène¹⁵,Macé Sandrine¹⁶,Risse Marie‐Laure¹⁶,Velde Helgi¹³,Richardson Paul¹⁷^ORCID

Affiliation:

1. Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne Victoria Australia

2. Centre Hospitalo‐universitaire (CHU) de Toulouse Institut Universitaire du Cancer de Toulouse‐Oncopole (IUCT‐O)Université de Toulouse, UPS Service d’Hématologie Toulouse France

3. University Hospital La Princesa and University Hospital Quironsalud Madrid Spain

4. North Shore Hospital Auckland New Zealand

5. Chang Gung Medical Foundation Taipei Taiwan

6. The Alfred Hospital MONASH University/Australian Centre for Blood Diseases Melbourne Victoria Australia

7. Evangelismos Hospital Athens Greece

8. Service d'Hématologie Hôpital Haut‐Lévêque CHU Bordeaux France

9. Department of Hematology National Hospital Organization Okayama Medical Center Okayama Japan

10. Department of Haematology Lille University Hospital Lille France

11. Department of Haematology Ghent University Hospital Ghent Belgium

12. Department of Haematology University College Hospital London UK

13. Sanofi Cambridge MA USA

14. Affiliation at time of study, currently Takeda Pharmaceuticals Cambridge MA USA

15. IT&M Stats (for Sanofi) Neuilly‐sur‐Seine, Île‐de‐FranceFrance

16. Sanofi R&D Vitry‐sur‐Seine France

17. Medical Oncology Dana‐Farber Cancer Institute Harvard Medical School BostonMAUSA

Funder

Fondation Sanofi Espoir

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17499

Reference33 articles.

1. The effect of novel therapies in high‐molecular‐risk multiple myeloma;Lancman G;Clin Adv Hematol Oncol,2017

2. The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma

3. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

4. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

5. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN;Blood Cancer Journal;2024-07-08

2. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma;New England Journal of Medicine;2024-06-03

3. Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature;Expert Opinion on Biological Therapy;2024-05-03

4. The numerous facets of 1q21⁺ in multiple myeloma: Pathogenesis, clinicopathological features, prognosis and clinical progress (Review);Oncology Letters;2024-04-09

5. Disease-controlled multiple myeloma in a patient with 17p gain and t(4;14): A case report;Heliyon;2024-04